NewLink Genetics Corporation (NASDAQ: NLNK) is one of 177 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare NewLink Genetics Corporation to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

45.3% of NewLink Genetics Corporation shares are owned by institutional investors. Comparatively, 46.2% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.7% of NewLink Genetics Corporation shares are owned by insiders. Comparatively, 13.9% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for NewLink Genetics Corporation and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewLink Genetics Corporation 0 0 6 0 3.00
NewLink Genetics Corporation Competitors 470 2234 6277 117 2.66

NewLink Genetics Corporation presently has a consensus price target of $25.67, indicating a potential upside of 167.08%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.87%. Given NewLink Genetics Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe NewLink Genetics Corporation is more favorable than its peers.

Earnings and Valuation

This table compares NewLink Genetics Corporation and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
NewLink Genetics Corporation $35.77 million -$85.15 million -3.94
NewLink Genetics Corporation Competitors $221.29 million -$39.79 million -73.01

NewLink Genetics Corporation’s peers have higher revenue and earnings than NewLink Genetics Corporation. NewLink Genetics Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

NewLink Genetics Corporation has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, NewLink Genetics Corporation’s peers have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Profitability

This table compares NewLink Genetics Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewLink Genetics Corporation -229.19% -63.39% -47.83%
NewLink Genetics Corporation Competitors -3,382.37% -92.28% -39.28%

Summary

NewLink Genetics Corporation peers beat NewLink Genetics Corporation on 7 of the 12 factors compared.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.